Evidence map›Paper›PMID 24778441›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Nicholas M Provine, Rafael A Larocca, Pablo Penaloza-MacMaster, Erica N Borducchi, Anna McNally, Lily R Parenteau, David R Kaufman, Dan H Barouch

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nicholas M ProvineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Rafael A LaroccaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Pablo Penaloza-MacMasterCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Anna McNallyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Lily R ParenteauCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
David R KaufmanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215; and Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139 dbarouch@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USRagon Institute of MGH, MIT and Harvard · US

Funding

Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 VaccineU19AI078526 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2008 to 2012
$44.0M
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 VaccinesU19AI096040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SEAMAN, MICHAEL SCOTT · 2012 to 2016
$18.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Trapping membrane proteins with adjuvant-carrying amphipols for vaccine formulatiR01AI092129 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI COCCO, MELANIE J, DE LA MAZA, LUIS M · 2011 to 2014
$1.3M
NIAID NIH HHS AI092129NIAID NIH HHS AI096040NIAID NIH HHS T32 AI007245NIAID NIH HHS U19 AI078526NIAID NIH HHS U19 AI096040
6 · The paper itself

Abstract

Despite the widespread use of replication-incompetent recombinant adenovirus (Ad) vectors as candidate vaccine platforms, the mechanism by which these vectors elicit CD8(+) T cell responses remains poorly understood. Our data demonstrate that induction and maintenance of CD8(+) T cell responses by Ad vector immunization is longitudinally dependent on CD4(+) T cell help for a prolonged period. Depletion of CD4(+) T cells in wild type mice within the first 8 d following Ad immunization resulted in dramatically reduced induction of Ag-specific CD8(+) T cells, decreased T-bet and eomesodermin expression, impaired KLRG1(+) effector differentiation, and atypical expression of the memory markers CD127, CD27, and CD62L. Moreover, these CD8(+) T cells failed to protect against a lethal recombinant Listeria monocytogenes challenge. Depletion of CD4(+) T cells between weeks 1 and 4 following immunization resulted in increased contraction of memory CD8(+) T cells. These data demonstrate a prolonged temporal requirement for CD4(+) T cell help for vaccine-elicited CD8(+) T cell responses in mice. These findings have important implications in the design of vaccines aimed at eliciting CD8(+) T cell responses and may provide insight into the impaired immunogenicity of vaccines in the context of AIDS and other CD4(+) T cell immune deficiencies.

Indexed as

AdenoviridaeAnimalsAntigens, CDBacterial VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesGenetic VectorsListeria monocytogenesListeriosisMiceMice, KnockoutAntigens, CDBacterial Vaccines

Identifiers

PMID24778441
PMCPMC4025612
OpenAlexW2158563602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.